The GPD2 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for targeted disruption of the human GPD2 gene in HAP1 near-haploid chronic myeloid leukemia cells. This product provides a versatile loss-of-function model for dissecting mitochondrial glycerol-3-phosphate dehydrogenase biology without the need for single-cell cloning, enabling population-level studies of gene disruption effects.
HAP1 cells are derived from the KBM-7 chronic myeloid leukemia line and adapted to a near-haploid karyotype, which enhances the efficiency of CRISPR/Cas9-mediated gene disruption and simplifies functional genetic analyses. These cells retain key signaling and metabolic features of their myeloid leukemia origin, making them a relevant host for studying metabolic gene function in a cancer context. Their near-haploidy reduces the complexity of biallelic editing outcomes, facilitating the generation of potent knockout populations.
GPD2 encodes the mitochondrial glycerol-3-phosphate dehydrogenase, a key enzyme of the glycerol phosphate shuttle that couples cytosolic glycolysis to mitochondrial oxidative phosphorylation. This homodimeric flavoprotein uses FAD to oxidize glycerol-3-phosphate to dihydroxyacetone phosphate, generating FADH2, then transfers electrons to ubiquinone, feeding into complex III of the electron transport chain. GPD2 expression and activity are transcriptionally regulated by factors such as PPARGC1A (PGC-1??), PPARA, CREB, and HIF1A, and respond to the NADH/NAD+ ratio and intracellular glycerol-3-phosphate levels. Downstream, the enzyme contributes to ATP synthesis via ATP synthase and influences reactive oxygen species production through electron flux modulation. Its activity intersects with gluconeogenesis, lipid metabolism, and overall cellular redox balance.
In HAP1 cells, disruption of GPD2 generates a powerful model to interrogate the dependence of leukemic cells on the glycerol phosphate shuttle for mitochondrial ATP production and redox homeostasis. Because HAP1 cells are derived from chronic myeloid leukemia, this knockout system allows researchers to probe how cancer cells adapt their bioenergetic pathways when this mitochondrial dehydrogenase is ablated, potentially revealing vulnerabilities related to metabolic flexibility and oxidative stress management. The polyclonal nature of the population ensures that studies capture a range of editing events, mirroring heterogeneous tumor cell responses.
The GPD2 Knockout HAP1 Polyclonal Cells are well-suited for a broad array of investigative workflows, including mitochondrial bioenergetics profiling via Seahorse metabolic flux analysis, measurement of lactate production to assess glycolytic shift, GPD2 enzymatic activity assays, Western blotting and RT-qPCR for confirmation of gene disruption and compensatory pathway analysis, and flow cytometry-based assessment of mitochondrial membrane potential. Metabolomics studies can further delineate alterations in the glycerol phosphate shuttle and related metabolic networks. These applications make the model valuable for target validation in metabolic diseases such as type 2 diabetes mellitus, obesity, and metabolic syndrome, as well as for cancer metabolism research and screening of small-molecule modulators. For additional information, please contact Ascent Research.
